|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:alsoKnownAs
|
Psychedelics
|
|
gptkbp:category
|
Psychoactive drug
Serotonergic psychedelic
|
|
gptkbp:duration
|
Varies by substance
|
|
gptkbp:effect
|
Altered perception
Altered cognition
Altered mood
|
|
gptkbp:effectOnBrain
|
gptkb:Synesthesia
Ego dissolution
Enhanced sensory perception
Decreased default mode network activity
Increased connectivity
|
|
gptkbp:example
|
gptkb:Mescaline
gptkb:Psilocybin
gptkb:DMT
gptkb:Ayahuasca
LSD
Peyote
Ergine
|
|
gptkbp:firstSynthesized
|
1938 (LSD)
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Classical hallucinogens
|
|
gptkbp:legalStatus
|
Varies by country
|
|
gptkbp:mechanismOfAction
|
Serotonin 5-HT2A receptor agonism
|
|
gptkbp:naturalOccurrence
|
gptkb:Cacti
gptkb:Fungi
gptkb:Plants
|
|
gptkbp:notableContributor
|
gptkb:Timothy_Leary
gptkb:Albert_Hofmann
gptkb:Roland_Griffiths
|
|
gptkbp:notableFor
|
Religious ceremonies
Shamanic rituals
Modern psychotherapy research
|
|
gptkbp:onset
|
Varies by substance
|
|
gptkbp:relatedTo
|
gptkb:Entheogens
gptkb:Dissociative_hallucinogens
Deliriants
|
|
gptkbp:riskFactor
|
gptkb:Anxiety
Bad trip
Hallucinogen persisting perception disorder
Psychosis (rare)
|
|
gptkbp:routeOfAdministration
|
gptkb:Oral
gptkb:Injection
Inhalation
|
|
gptkbp:usedFor
|
Recreational purposes
Spiritual purposes
Therapeutic research
|
|
gptkbp:bfsParent
|
gptkb:Hallucinogens
|
|
gptkbp:bfsLayer
|
7
|